Copy to clipboard 
Shoulder Innovations reported 1Q26 orthopedic sales of $16.7 million, up 64.9% compared to the first quarter of 2025.
The company’s growth was driven by the rapid onboarding of surgeons, deeper utilization from existing customers and new product milestones.
Leadership remains focused on the approximately 1,800 high-volume shoulder specialists in the U.S., which has translated to rapid growth for the company.
“First, surgeons are entering our new customer funnel faster,” said Shoulder Innovations CEO Rob Ball. “In fact, in the first quarter, we more than doubled the number of new customers entering our funnel as compared to the first quarter of 2025. Second, surgeons are scaling through the funnel from prospect to contender to core at a faster pace. And third, we’re seeing increased volume from existing surgeons within their current prospect contender and core categories.”
The company’s expanding indications for product lines is helping to support deeper utilization, such as the commercial launch of the I-135RFX. With the broader label, the I-135 family can now address primary revision and fracture total shoulder arthroplasty cases. Shoulder Innovations is also targeting a 510(k) submission for its micro-robot in 2027.
Given the strong start to the year, the company now expects 2026 sales between $65 million and $68 million, representing growth between 37% and 44% over 2025.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Extremity Joint Replacement | $16.7 | $10.1 | $6.6 | 64.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $16.7 | |
| Cost of Sales | $3.7 | 22.3% |
| Sales and Marketing | $18.2 | 109% |
| R & D | $3.8 | 22.5% |
| Other | ($0.4) | (2.5%) |
| Net Earnings | ($8.6) | (51.2%) |
Shoulder Innovations reported 1Q26 orthopedic sales of $16.7 million, up 64.9% compared to the first quarter of 2025.
The company's growth was driven by the rapid onboarding of surgeons, deeper utilization from existing customers and new product milestones.
Leadership remains focused on the approximately 1,800 high-volume shoulder...
Shoulder Innovations reported 1Q26 orthopedic sales of $16.7 million, up 64.9% compared to the first quarter of 2025.
The company’s growth was driven by the rapid onboarding of surgeons, deeper utilization from existing customers and new product milestones.
Leadership remains focused on the approximately 1,800 high-volume shoulder specialists in the U.S., which has translated to rapid growth for the company.
“First, surgeons are entering our new customer funnel faster,” said Shoulder Innovations CEO Rob Ball. “In fact, in the first quarter, we more than doubled the number of new customers entering our funnel as compared to the first quarter of 2025. Second, surgeons are scaling through the funnel from prospect to contender to core at a faster pace. And third, we’re seeing increased volume from existing surgeons within their current prospect contender and core categories.”
The company’s expanding indications for product lines is helping to support deeper utilization, such as the commercial launch of the I-135RFX. With the broader label, the I-135 family can now address primary revision and fracture total shoulder arthroplasty cases. Shoulder Innovations is also targeting a 510(k) submission for its micro-robot in 2027.
Given the strong start to the year, the company now expects 2026 sales between $65 million and $68 million, representing growth between 37% and 44% over 2025.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Extremity Joint Replacement | $16.7 | $10.1 | $6.6 | 64.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $16.7 | |
| Cost of Sales | $3.7 | 22.3% |
| Sales and Marketing | $18.2 | 109% |
| R & D | $3.8 | 22.5% |
| Other | ($0.4) | (2.5%) |
| Net Earnings | ($8.6) | (51.2%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
